Agios Pharm

NASDAQ AGIO

Download Data

Agios Pharm Long-Term Debt to Total Assets Ratio 2 year CAGR for the quarter ending September 20, 2024

Agios Pharm Long-Term Debt to Total Assets Ratio 2 year CAGR is NA for the quarter ending September 20, 2024. The long-term debt to total assets ratio measures the proportion of a company's long-term debt to its total assets. It is calculated by dividing the long-term debt by the total assets. This ratio indicates the extent to which a company's assets are financed by long-term debt. A higher ratio suggests a higher level of long-term debt relative to total assets, which can indicate increased financial risk and affect the company's ability to generate returns for its shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: AGIO

Agios Pharm

CEO Dr. Bruce D. Car DACVP, Ph.D.
IPO Date July 24, 2013
Location United States
Headquarters 88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees 383
Sector Healthcare
Industry Biotechnology
Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

STOK

Stoke Therapeutics Inc

NA

NA

COGT

Cogent Biosciences Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

KALV

Kalvista Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email